[
    [
        {
            "time": "",
            "original_text": "天坛生物子公司拟4.96亿元新建重组凝血因子生产车间及动物房",
            "features": {
                "keywords": [
                    "天坛生物",
                    "子公司",
                    "重组凝血因子",
                    "生产车间",
                    "动物房",
                    "投资"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "天坛生物子公司拟4.96亿元新建重组凝血因子生产车间及动物房",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天坛生物：一季度净利润同比减少32.9% 盈利能力下降",
            "features": {
                "keywords": [
                    "天坛生物",
                    "一季度",
                    "净利润",
                    "同比下降",
                    "盈利能力"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "天坛生物：一季度净利润同比减少32.9% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【国元医药】天坛生物2020Q1点评：血浆成本略有提升，投资重组因子车间",
            "features": {
                "keywords": [
                    "国元医药",
                    "天坛生物",
                    "2020Q1",
                    "血浆成本",
                    "提升",
                    "投资",
                    "重组因子车间"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【国元医药】天坛生物2020Q1点评：血浆成本略有提升，投资重组因子车间",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]